U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07900165) titled 'Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer' on Oct. 21.
Brief Summary: This is a non-registrational Phase 1/2, multicenter, open-label trial to evaluate the efficacy and safety of varsetatug masetecan combined with anti-cancer therapies in participants with unresectable metastatic colorectal cancer in the second line treatment setting.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Colo-rectal Cancer
Intervention:
DRUG: varsetatug masetecan
Investigational Product
DRUG: bevacizumab + 5-FU + leucovorin
IV infusion
DRUG: bevacizumab
IV infusion
Recruitme...